Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain
- PMID: 15652293
- DOI: 10.1016/j.micpath.2004.10.007
Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain
Abstract
In order to evaluate the immunogenicity and protective efficacy of anthrax vaccine candidates a suitable small animal model is required. The inbred A/J strain of mouse has been selected as a potential model, and its immune response to immunisation with recombinant protective antigen (rPA) vaccine characterised, by assessment of rPA specific antibody production, and protection against injected challenge, with the unencapsulated STI strain of Bacillus anthracis. Studies were conducted to determine the time required post immunisation to develop a protective immune response, to define the minimum protective dose of vaccine required and to assess the long-term immune response to immunisation. From the results of these studies it was possible to establish that the A/J mouse is a consistent and robust small animal model for rPA vaccine testing. A comparison of the immune response to rPA vaccine immunisation in the Turner Outbred (TO) mouse strain was also conducted. Both inbred and outbred mouse strains displayed a predominantly Th2 biased immune response and showed a comparable antibody response to rPA immunisation. An assessment of protection in the TO mouse against aerosol challenge with the fully virulent strain of B. anthracis, Ames, was also made.
Similar articles
-
Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.Vaccine. 2008 Oct 23;26(45):5684-8. doi: 10.1016/j.vaccine.2008.08.026. Epub 2008 Sep 4. Vaccine. 2008. PMID: 18775462
-
Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.Vaccine. 2006 Mar 24;24(14):2530-6. doi: 10.1016/j.vaccine.2005.12.028. Epub 2005 Dec 27. Vaccine. 2006. PMID: 16417950
-
Anthrax capsule vaccine protects against experimental infection.Vaccine. 2004 Nov 15;23(1):43-7. doi: 10.1016/j.vaccine.2004.05.029. Vaccine. 2004. PMID: 15519706
-
Progress and novel strategies in vaccine development and treatment of anthrax.Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Immunol Rev. 2011. PMID: 21198675 Review.
-
Molecular basis for improved anthrax vaccines.Adv Drug Deliv Rev. 2005 Jun 17;57(9):1266-92. doi: 10.1016/j.addr.2005.01.028. Epub 2005 Apr 21. Adv Drug Deliv Rev. 2005. PMID: 15935874 Review.
Cited by
-
Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice.Neuromolecular Med. 2007;9(1):83-100. doi: 10.1385/nmm:9:1:83. Neuromolecular Med. 2007. PMID: 17114826
-
The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.FEMS Immunol Med Microbiol. 2011 Jul;62(2):164-72. doi: 10.1111/j.1574-695X.2011.00800.x. Epub 2011 Apr 15. FEMS Immunol Med Microbiol. 2011. PMID: 21401726 Free PMC article.
-
Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus).Int J Exp Pathol. 2008 Jun;89(3):171-9. doi: 10.1111/j.1365-2613.2008.00581.x. Int J Exp Pathol. 2008. PMID: 18460069 Free PMC article.
-
A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.Protein Expr Purif. 2008 Jan;57(1):72-80. doi: 10.1016/j.pep.2007.08.016. Epub 2007 Sep 14. Protein Expr Purif. 2008. PMID: 18029197 Free PMC article.
-
A multipathogen DNA vaccine elicits protective immune responses against two class A bioterrorism agents, anthrax and botulism.Appl Microbiol Biotechnol. 2022 Feb;106(4):1531-1542. doi: 10.1007/s00253-022-11812-6. Epub 2022 Feb 10. Appl Microbiol Biotechnol. 2022. PMID: 35141866 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical